Your browser doesn't support javascript.
loading
Double-Blind Multicenter Randomized Clinical Trial Comparing Glucagon vs Placebo in the Resolution of Alimentary Esophageal Impaction.
de Benito Sanz, Marina; Tejedor-Tejada, Javier; Mangas-Sanjuan, Carolina; Santa, Eva de la; Cebrian, Irene; Talegón, Raquel; Sánchez-Ocaña, Ramón; Pérez-Pariente, José M; Pérez-Miranda, Manuel; García-Alonso, Francisco Javier.
Afiliação
  • de Benito Sanz M; Department of Gastroenterology, Hospital Universitario Rio Hortega, Valladolid, Spain.
  • Tejedor-Tejada J; Department of Gastroenterology, Hospital de Cabueñes, Gijón, Spain.
  • Mangas-Sanjuan C; Department of Gastroenterology, Hospital General Universitario de Alicante, Alicante, Spain.
  • Santa E; Department of Gastroenterology, Hospital de Ciudad Real, Ciudad Real, Spain.
  • Cebrian I; Emergency Department, Hospital Universitario Rio Hortega, Valladolid, Spain.
  • Talegón R; Emergency Department, Hospital Universitario Rio Hortega, Valladolid, Spain.
  • Sánchez-Ocaña R; Department of Gastroenterology, Hospital Universitario Rio Hortega, Valladolid, Spain.
  • Pérez-Pariente JM; Department of Gastroenterology, Hospital de Cabueñes, Gijón, Spain.
  • Pérez-Miranda M; Department of Gastroenterology, Hospital Universitario Rio Hortega, Valladolid, Spain.
  • García-Alonso FJ; Department of Gastroenterology, Hospital Universitario Rio Hortega, Valladolid, Spain.
Am J Gastroenterol ; 119(1): 87-96, 2024 Jan 01.
Article em En | MEDLINE | ID: mdl-37734342
ABSTRACT

INTRODUCTION:

The aim of this study was to compare the effectiveness of glucagon vs placebo in resolving esophageal foreign body impaction (EFBI), as well as the length of the procedure and adverse events.

METHODS:

This was a multicenter, randomized, double-blind trial involving consecutive patients diagnosed with alimentary EFBI. Participants were randomized to receive either 1 mg of intravenous glucagon or placebo. All patients underwent upper endoscopy, and adverse events were assessed through a protocolized telephonic interview 7 days later.

RESULTS:

The study included 72 subjects in the glucagon group and 68 in the placebo group. The foreign body was not identified in 23.6% of subjects in the glucagon group and 20.6% of subjects in the placebo group (difference 3%, 95% confidence interval -10.7% to 16.8%, P = 0.67). The median time required to remove the foreign body was similar in both groups 4 minutes (range 2-10) in the glucagon group and 3.5 minutes (range 2-7) in the placebo group (difference 0.5 minutes, 95% confidence interval -1.3 to 2.3; P = 0.59). The most common adverse event reported in both groups was mild pharyngeal pain.

DISCUSSION:

Glucagon is no more effective than placebo in resolving EFBI or shortening the time required to remove the foreign body (EUDRA-CT number 2019-004920-40).
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glucagon / Corpos Estranhos Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Glucagon / Corpos Estranhos Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article